A platform for designing genome-based personalized immunotherapy or vaccine against cancer

12Citations
Citations of this article
61Readers
Mendeley users who have this article in their library.

Abstract

Due to advancement in sequencing technology, genomes of thousands of cancer tissues or cell-lines have been sequenced. Identification of cancer-specific epitopes or neoepitopes from cancer genomes is one of the major challenges in the field of immunotherapy or vaccine development. This paper describes a platform Cancertope, developed for designing genome-based immunotherapy or vaccine against a cancer cell. Broadly, the integrated resources on this platform are apportioned into three precise sections. First section explains a cancer-specific database of neoepitopes generated from genome of 905 cancer cell lines. This database harbors wide range of epitopes (e.g., B-cell, CD8+ T-cell, HLA class I, HLA class II) against 60 cancer-specific vaccine antigens. Second section describes a partially personalized module developed for predicting potential neoepitopes against a user-specific cancer genome. Finally, we describe a fully personalized module developed for identification of neoepitopes from genomes of cancerous and healthy cells of a cancer-patient. In order to assist the scientific community, wide range of tools are incorporated in this platform that includes screening of epitopes against human reference proteome (http://www.imtech.res.in/raghava/cancertope/).

Cite

CITATION STYLE

APA

Gupta, S., Chaudhary, K., Dhanda, S. K., Kumar, R., Kumar, S., Sehgal, M., … Raghava, G. P. S. (2016). A platform for designing genome-based personalized immunotherapy or vaccine against cancer. PLoS ONE, 11(11). https://doi.org/10.1371/journal.pone.0166372

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free